Maravai LifeSciences Holdings, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | $288.9M | $883.0M | $799.2M | $284.1M | $143.1M |
| Cost of Revenue | $151.8M | $150.9M | $148.7M | $169.0M | $140.6M | $79.6M | $66.8M |
| Gross Profit | $34.0M | $108.3M | $140.2M | $714.0M | $658.7M | $204.4M | $76.3M |
| Gross Margin | 18.3% | 41.8% | 48.5% | 80.9% | 82.4% | 72.0% | 53.3% |
| Operating Expenses | |||||||
| Research & Development | $17.4M | $19.2M | $17.3M | $18.4M | $15.2M | $9.3M | $3.6M |
| SG&A Expense | $145.1M | $161.8M | $151.4M | $129.3M | $100.1M | $94.2M | $48.4M |
| Operating Income | $-215.3M | $-235.6M | $-31.6M | $574.2M | $554.6M | $119.9M | $24.0M |
| Operating Margin | -115.9% | -90.9% | -11.0% | 65.0% | 69.4% | 42.2% | 16.8% |
| Interest Expense | — | — | $45.9M | $20.4M | $30.3M | $30.7M | $30.0M |
| Pretax Income | $-235.0M | $-261.5M | $617.7M | $551.5M | $530.8M | $81.7M | $-5.9M |
| Income Tax Expense | $-4.2M | $-1.9M | $756.1M | $60.8M | $61.5M | $2.9M | $-652.0K |
| Net Income | $-130.8M | $-144.8M | $-119.0M | $220.2M | $182.0M | $89.0M | $-4.5M |
| Net Margin | -70.4% | -55.9% | -41.2% | 24.9% | 22.8% | 31.3% | -3.1% |
| EPS (Basic) | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.59 | $0.83 | $0.00 |
| EPS (Diluted) | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 | $0.26 | $0.00 |
| Shares Outstanding (Basic) | 144.4M | 137.9M | 131.9M | 131.5M | 114.8M | 93.2M | 2.29B |
| Shares Outstanding (Diluted) | 144.4M | 137.9M | 131.9M | 255.3M | 257.8M | 260.2M | 2.29B |
| Dividends Per Share | — | — | — | — | — | — | — |